VettaFi Research·2026-06-25·via All Articles on Seeking Alpha
Summary
CRISPR Therapeutics, co-developer of the CASGEVY gene-editing cure for sickle cell disease and beta-thalassemia, was added to HTEC. The company brings an advanced pipeline of therapies targeting cardiovascular and autoimmune diseases.
Insilico Medicine joins HTEC as its first pure-play AI drug discovery company, generating 6 to 8 preclinical candidates annually and projecting $1,287MM in FY 2026 revenue.
Compass Pathways was added to the index following its final, large-scale trials for COMP360, a synthetic psilocybin treatment that provided three to six months of relief for treatment-resistant depression during clinical trials.
Tom Werner/DigitalVision via Getty Images
By Rafael Silva
The Healthcare Technology and Innovation index (HTEC) was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address
